You are here

P&T® Journal contents for November 2002


Pharmaceutical-Approval Update
Marvin M. Goldenberg, PhD, describes new treatments for colorectal, breast, and advanced prostate cancer.
Marvin M. Goldenberg, PhD
It is possible to safely reduce the dose of medication for patients with GERD.
Cameron C. Lindsey, PharmD, Maqual R. Graham, PharmD, and Lauri A. Witt, PharmD
A unique antibiotic monitoring program has succeeded in reducing costs.
Arpi G. Kuyumjian, PharmD, Jerome F. Levine, MD, Peter A. Gross, MD, and Antonia Lo Presti, MD
New COX-1/COX-2 NSAIDs relieve pain with less gastrointestinal damage than past pain relievers but may increase the risk of cardiovascular injury.
Richard L. Ruffalo, MD, PharmD, Robert L. Jackson, MD, and Joshua J. Ofman, MD, MSHS
The authors review the potential gastrointestinal and cardiovascular risks posed by COX-1/COX-2 NSAIDs.
A. Mark Fendrick, MD, and Susan M. Garabedian-Ruffalo, PharmD
Guest Commentary
The difficulty in educating professionals who prescribe medications is not unlike the challenge of fixing a dangerous road.
Peter Teichman, MD, MPA


Editor-in-Chief David Nash discusses the National Drug and Therapeutic Index.
David B. Nash, MD, MBA
Medication Errors
Precautions must be taken when sample medications are dispensed.
Matthew Grissinger
Drug News
The latest information about approvals, indication changes, industry updates, and news from the FDA.
Prescription Washington
Mr. Barlas discusses the ambiguity of the new federal guidelines for PBMs.
Stephen Barlas
Drug Forecast
Omalizumab is being touted as a new treatment for patients with allergic disorders.
Boris Nogid, PharmD, and Timothy S. McCall, RPh